1. Home
  2. FFIC vs DSGN Comparison

FFIC vs DSGN Comparison

Compare FFIC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flushing Financial Corporation

FFIC

Flushing Financial Corporation

HOLD

Current Price

$17.30

Market Cap

557.3M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

BUY

Current Price

$9.73

Market Cap

504.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FFIC
DSGN
Founded
1929
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.3M
504.7M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FFIC
DSGN
Price
$17.30
$9.73
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
259.6K
442.6K
Earning Date
01-27-2026
11-05-2025
Dividend Yield
5.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$143,853,000.00
N/A
Revenue This Year
$113.60
N/A
Revenue Next Year
$7.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.65
$2.60
52 Week High
$17.79
$10.31

Technical Indicators

Market Signals
Indicator
FFIC
DSGN
Relative Strength Index (RSI) 67.19 59.93
Support Level $17.13 $8.69
Resistance Level $17.31 $9.68
Average True Range (ATR) 0.40 0.72
MACD -0.01 -0.11
Stochastic Oscillator 69.50 65.80

Price Performance

Historical Comparison
FFIC
DSGN

About FFIC Flushing Financial Corporation

Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: